To further explore the possibility and applicability of the risk model constructed in a clinical setting, based on the recent acceptance of cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1) checkpoint blockade of the immune response data of melanoma patients treated, the subgraph method was used to predict the responsiveness of the high- and low-risk groups to immunotherapy. Here, CTLA4 is linked to melanoma.